MoonLake Immunotherapeutics
sonelokimab
hidradenitis suppurativa
Countdown
86days
Catalyst readout · ~ Sep 30, 2026 estimated
What's at stake
A key catalyst for sonelokimab (hidradenitis suppurativa) is expected ~ Sep 30, 2026.
Primary source
· SEC 8-K
verified 13h ago
“Submission of the Biologics License Application (BLA) for SLK in HS, including data from adolescent patients, is expected at the end of September 2026.”